



Experience
INDIAN
HEALTHCARE

Poly Medicure Ltd.

POLYMED
Medical Devices

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate, Phase - III, New Delhi - 110020, INDIA
Tel : +91-11-47317000, 33550700, 26321838 / 81 / 89 / 93 / 99, Fax : +91-11-26321894, 26321839
E-mail : info@polymedicure.com Website : www.polymedicure.com
CIN : L40300DL1995PLC066923

Date: 19th May, 2017

Scrip Code: - 531768

The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Kind Attention: Mr. Rakesh Parekh

Sub: Discrepancies in Financial Result of the Company for the quarter\ year ended March 2017

Dear Sir,

With reference to your e-mail dated 17th May, 2017 regarding the subject matter, Please find attached the Audited Financial Results (Standalone and Consolidated) of our Company in the format as per Schedule III to the Companies Act, 2013 and Declaration of impact of Unmodified Audit Qualifications (Standalone & Consolidated).

Kindly take a note of the same for your further needful and oblige us.

Thanking You,

Yours Sincerely

For Poly Medicure Limited

Avinash Chandra
Company Secretary



POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020, Phone: 011-26321889, Fax: 011-26321894

Website: polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

STATEMENT OF STANDALONE / CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2017

₹ in lacs

	Particulars	Standalone					Consolidated	
		Quarter ended			Year ended		Year ended	
		31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016	31.03.2017	31.03.2016
		(Unaudited)			(Audited)		(Audited)	
I	Revenue from operations (net of excise duty)	11,808.71	11,391.51	10,676.11	43,978.19	39,447.84	45,528.96	41,225.72
II	Other income	399.11	289.23	194.26	1,111.15	838.50	1,108.89	826.59
III	Total Revenue (net) (i+II)	12,207.82	11,680.74	10,870.37	45,089.34	40,286.34	46,637.85	42,052.31
IV	Expenses							
a	Cost of materials consumed	4,013.61	3,691.69	3,210.22	14,500.24	13,177.29	15,066.33	14,091.66
b	Purchases of stock-in-trade	98.17	162.34	154.23	568.46	676.13	568.46	676.13
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	202.79	(210.03)	265.72	(426.62)	200.25	(289.67)	21.03
d	Employee benefits expense	2,036.44	2,118.61	1,853.94	8,159.71	6,899.23	8,746.10	7,477.49
e	Finance costs	155.18	197.60	205.45	700.54	778.24	723.16	797.14
f	Depreciation and amortisation expense	618.74	588.02	509.11	2,291.92	2,018.79	2,368.96	2,102.89
g	Other expenses	3,452.71	3,026.23	2,577.25	11,958.05	10,048.79	12,283.59	10,381.81
	Total expenses	10,577.64	9,574.46	8,775.92	37,752.30	33,798.72	39,466.93	35,548.15
V	Profit before exceptional and extraordinary items and tax (III - IV)	1,630.18	2,106.28	2,094.45	7,337.04	6,487.62	7,170.92	6,504.16
VI	Exceptional items	-	-	-	-	-	-	-
VII	Profit before extraordinary items and tax (V - VI)	1,630.18	2,106.28	2,094.45	7,337.04	6,487.62	7,170.92	6,504.16
VIII	Extraordinary items	-	-	-	-	-	-	-
IX	Profit before tax (VII- VIII)							
X	Tax expense							
1	Current Tax with Tax adjustments for earlier years	174.47	536.97	572.57	1,707.44	1,601.98	1,707.44	1,601.98
2	Deferred Tax	128.87	65.79	81.32	290.26	154.89	290.26	154.89
XI	Profit (Loss) for the period from continuing operations (IX-X)	1,326.84	1,503.52	1,440.56	5,339.34	4,730.75	5,173.22	4,747.29
XII	Profit/(loss) from discontinuing operations	-	-	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)							
XV	Profit (Loss) for the period (XI + XIV)	1,326.84	1,503.52	1,440.56	5,339.34	4,730.75	5,173.22	4,747.29
XVI	Share of profit / (loss) of associates						58.71	79.50
XVII	Loss attributable to Minority interest						-	-
XVIII	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (XV+XVI+XVII)	1,326.84	1,503.52	1,440.56	5,339.34	4,730.75	5,231.93	4,826.79
XIX	Earnings per share (refer note 5) (Quarterly not annualised and yearly annualised) :							
	Basic (₹)	1.50	1.71	1.64	6.05	5.36	5.93	5.47
	Diluted (₹)	1.50	1.71	1.64	6.05	5.36	5.93	5.47

Statement of Assets and Liabilities					
Particulars	Standalone		Consolidated		
	As at		As at		
	31.03.2017	31.03.2016	31.03.2017	31.03.2016	
	Audited	Audited	Audited	Audited	
A EQUITY AND LIABILITIES					
1 Shareholders' funds					
(a) Share capital	4,411.34	2,205.67	4,411.34	2,205.67	
(b) Reserves and surplus	21,793.55	20,177.89	22,029.92	20,657.47	
Sub-total - Shareholders' funds	26,204.89	22,383.56	26,441.26	22,863.14	
2 Minority interest	-	-	(0.26)	(0.26)	
3 Non-current liabilities					
(a) Long-term borrowings	4,768.85	3,106.28	4,768.85	3,106.28	
(b) Deferred tax liabilities (net)	1,473.63	1,183.37	1,473.63	1,183.37	
(c) Other long-term liabilities	507.83	401.94	507.83	401.94	
(d) Long-term provisions	332.58	256.51	332.58	256.51	
Sub-total - Non-current liabilities	7,082.89	4,948.10	7,082.89	4,948.10	
4 Current liabilities					
(a) Short-term borrowings	2,849.66	3,039.38	3,229.90	3,345.59	
(b) Trade payables	4,098.21	2,957.53	4,185.52	3,087.15	
(c) Other current liabilities	3,846.00	3,797.33	3,950.95	3,988.98	
(d) Short-term provisions	569.20	503.08	569.20	503.08	
Sub-total - Current liabilities	11,363.07	10,297.32	11,935.57	10,924.80	
TOTAL - EQUITY AND LIABILITIES	44,650.85	37,628.98	45,459.46	38,735.78	
B ASSETS					
1 Non-current assets					
(a) Fixed assets	21,838.86	19,096.77	22,397.12	19,606.52	
(b) Non-current investments	561.06	561.06	327.72	442.21	
(c) Long-term loans and advances	1,765.22	1,290.91	1,765.22	1,290.91	
(d) Other non-current assets	426.56	336.47	426.55	336.47	
Sub-total - Non-current assets	24,591.70	21,285.21	24,916.61	21,676.11	
2 Current assets					
(a) Inventories	5,988.85	4,058.25	6,392.63	4,600.04	
(b) Trade receivables	9,525.32	8,073.02	9,553.11	8,297.71	
(c) Cash and cash equivalents	2,248.99	2,147.87	2,278.19	2,172.55	
(d) Short-term loans and advances	1,441.43	1,283.06	1,460.63	1,226.84	
(e) Other current assets	854.56	781.57	858.29	762.53	
Sub-total - Current assets	20,059.15	16,343.77	20,542.85	17,059.67	
TOTAL - ASSETS	44,650.85	37,628.98	45,459.46	38,735.78	

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 10th May
- The Board of Directors have recommended a final dividend of 10% (₹ 0.50 per equity share), subject to approval of shareholders.
- The figures of last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended 31st March and the unaudited published year-to-date figures upto the third quarter ended 31st December.
- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable primary segments as per Accounting Standard-17.
- EPS for the year ended 31st March 2016 and for all comparable period have been reinstated to give impact of issue of bonus shares in financial year 2016-17.
- The consolidated Financial Statement has been prepared in accordance with AS- 21 " Consolidated Financial Statements" and AS-23 " Accounting for investment in Associates in Consolidated financial Statements".
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

Place : New Delhi
Date : 10.05.2017



By order of the Board
Himanshu Baid
Himanshu Baid
Managing Director



POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020,

Phone: 011-26321889, Fax: 011-26321894

Website: polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

EXTRACT OF STANDALONE / CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2017

₹ in lacs

	Particulars	Standalone			Consolidated		
		Qtr. Ended	Year Ended		Qtr. Ended	Year Ended	
		31.03.2017	31.03.2017	31.03.2016	31.03.2016	31.03.2017	31.03.2016
		(Unaudited)	(Audited)		(Unaudited)	(Audited)	
1	Income from operations	11,991.33	44,663.66	40,015.44	10,826.06	46,214.43	41,793.32
2	Net Profit from ordinary activities after tax	1,326.84	5,339.34	4,730.75	1,440.56	5,231.93	4,826.79
3	Net Profit for the period after tax (after Extraordinary items)	1,326.84	5,339.34	4,730.75	1,440.56	5,231.93	4,826.79
4	Paid up Equity Share Capital (Face Value ₹ 5 each)	4,411.34	4,411.34	2,205.67	2,205.67	4,411.34	2,205.67
5	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	21,793.55	21,793.55	20,177.89	20,177.89	22,029.92	20,657.47
		(As at 31.03.17)		(As at 31.03.16)			
6	Earnings per share (before extraordinary items) (Quarterly not annualised and yearly annualised) :						
	Basic (₹)	1.50	6.05	5.36	1.64	5.93	5.47
	Diluted (₹)	1.50	6.05	5.36	1.64	5.93	5.47

Note: The above is an extract of the detailed format of standalone Quarterly and Annual Financial Results (standalone and consolidated) filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the standalone and consolidated Annual Financial Results are available on the Stock Exchange websites, www.bseindia.com, www.nseindia.com and on the company website www.polymedicure.com

EPS for the year ended 31st March 2016 and for all comparable period have been reinstated to give impact of issue of bonus share in financial year 2016-

By order of the Board




Himanshu Baid

Managing Director

Place : New Delhi

Date : 10.05.2017





Poly Medicure Ltd.

POLYMED
Medical Devices

Works : Plot No. 104-105, Sector-59, HSIIDC Industrial Area, Ballabgarh, Faridabad-121004, INDIA
Phone : +91-129-4287000, 3355070, Fax : +91-129-2307007, 2309102
E-mail : info@polymedicure.com, Website : www.polymedicure.com
CIN : L40300DL1995PLC066923

Date: 18th May, 2017

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Declaration of impact of Un-modified Audit Qualifications (Standalone & Consolidated)

Ref: Compliance of Regulation 30 (3)(d) of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

In Compliance of Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, We hereby declare that M/s. Doogar & Associates (Statutory Auditors) of the Company have issued Audit Report with un-modified opinion on the Audited Financial Results (Standalone & Consolidated) for the fourth quarter and financial year ended on 31st March, 2017.

Kindly take a note of the same for your further needful and oblige us.

Thanking You,

Yours Sincerely

For Poly Medicure Limited

J. K. Oswal
C.F.O

